Sanofi Discloses 7% Stake in Lava Therapeutics

 

1.		Names of Reporting Persons     SANOFI
2.		Check the Appropriate Box if a Member of a Group (See Instructions)   (a)  ☐        (b)  ☐
3.		SEC Use Only
4.		Citizenship or Place of Organization     The Republic of France

Number of Shares  Beneficially  Owned by Each Reporting Person With				5.		Sole Voting Power     1,919,455 shares
				6.		Shared Voting Power     0 share
				7.		Sole Dispositive Power     1,919,455 shares
				8.		Shared Dispositive Power     0 share

9.		Aggregate Amount Beneficially Owned by Each Reporting Person     1,919,455 shares
10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     ☐
11.		Percent of Class Represented by Amount in Row (9)   7.0%
12.		Type of Reporting Person (See Instructions)     CO

 

2

---

Item 1.
		(a)		Name of Issuer LAVA Therapeutics N.V.
		(b)		Address of Issuer’s Principal Executive Offices Yalelaan 60, 3584 CM Utrecht, The Netherlands
Item 2.
		(a)		Name of Person Filing Sanofi
		(b)		Address of Principal Business Office or, if none, Residence 54 Rue La Boétie, 75008 Paris (France)
		(c)		Citizenship The Republic of France
		(d)		Title of Class of Securities Common Shares, €0.12 par value
		(e)		CUSIP Number N51517105
Item 3.		If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
		(a)		☐		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
		(b)		☐		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
		(c)		☐		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
		(d)		☐		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
		(e)		☐		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
		(f)		☐		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
		(g)		☐		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
		(h)		☐		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
		(i)		☐		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
		(j)		☐		A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
		(k)		☐		Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

 

3

---

Item 4.		Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
		(a)		Amount beneficially owned: 1,919,455 shares
		(b)		Percent of class: 7.0%
		(c)		Number of shares as to which the person has:
				(i)		Sole power to vote or to direct the vote 1,919,455 shares
				(ii)		Shared power to vote or to direct the vote 0 share
				(iii)		Sole power to dispose or to direct the disposition of 1,919,455 shares
				(iv)		Shared power to dispose or to direct the disposition of 0 share https://www.streetinsider.com/SEC+Filings/Form+SC+13G+LAVA+Therapeutics+NV+Filed+by%3A+Sanofi/18203652.html